Influence of dyslipidemia on moxidectin distribution in plasma lipoproteins and on its pharmacokinetics

Pharmaceutical Research

Volumn 23, Issue 11, 2006, Pages 2672-2680

  Bassissi, Mohamad Firas ^a   Alvinerie, Michel ^a   Martin, Pascal Guy Pierre ^a   Perret, Bertrand ^b   Lespine, Anne ^a  

^a CEMAGREF   (France)

^b CHU PURPAN   (France)

Author keywords

Antiparasitic; Hyperlipidemia; Lipoproteins; Macrocyclic lactones; Moxidectin; Pharmacokinetics

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MOXIDECTIN; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHOLESTEROL DIET; COMPARATIVE STUDY; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DRUG BINDING; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISCRIMINATION; DRUG DISPOSITION; DRUG STRUCTURE; DYSLIPIDEMIA; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; ULTRACENTRIFUGATION;

ANIMALS; DYSLIPIDEMIAS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MACROLIDES; MALE; RABBITS;

EID: 33750631017     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9114-2     Document Type: Article

References (40)

1. Q. A. McKellar and H. A. Benchaoui. Avermectins and milbemycins. J. Vet. Pharmacol. Ther. 19:331-351 (1996).
2. A. J. Trees, S. P. Graham, A. Renz, A. E. Bianco, and V. Tanya. Onchocerca ochengi infections in cattle as a model for human onchocerciasis: recent developments. Parasitology 120(Suppl):S133-S142 (2000).
3. C. Genchi, G. Poglayen, L. H. Kramer, L. Venco, and A. Agostini. Efficacy of moxidectin for the prevention of adult heartworm (Dirofilaria immitis) infection in dogs. Parassitologia 43:139-141 (2001).
4. L. Rossi, E. Ferroglio, and A. Agostini. Use of moxidectin tablets in the control of canine subcutaneous dirofilariosis. Vet. Rec. 150:383 (2002).
5. C. A. Guzzo, C. I. Furtek, A. G. Porras, C. Chen, R. Tipping, C. M. Clineschmidt, D. G. Sciberras, J. Y. Hsieh, and K. C. Lasseter. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J. Clin. Pharmacol. 42:1122-1133 (2002).
6. D. H. Molyneux, M. Bradley, A. Hoerauf, D. Kyelem, and M. J. Taylor. Mass drug treatment for lymphatic filariasis and onchocerciasis trends Parasitol. 19:516-522 (2003)
7. M. M. Cotreau, S. Warren, J. L. Ryan, L. Fleckenstein, S. R. Vanapalli, K. R. Brown, D. Rock, C. Y. Chen, and U. S. Schwertschlag. The antiparasitic moxidectin: safety, tolerabil ity, and pharmacokinetics in humans. J. Clin. Pharmacol. 43:1108-1115 (2003).
8. D. R. Hennessy and M. R. Alvinerie. Pharmacocinetics of the macrocyclic lactones: conventional wisdom and new paradigms. In J. Vercruysse and R. S. Rew (eds.), Macrocyclic Lactones and Antiparasitic Therapy, CAB International, Wallingford, 2002, pp. 97-123.
9. M. F. Bassissi, M. Alvinerie, and A. Lespine. Macrocyclic lactones: distribution in plasma lipoproteins of several animal species including humans. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 138:437-444 (2004).
10. S. H. Chiu, E. Sestokas, R. Taub, R. P. Buhs, M. Green, R. Sestokas, W. J. Vandenheuvel, B. H. Arison, and T. A. Jacob. Metabolic disposition of ivermectin in tissues of cattle, sheep, and rats. Drug Metab. Dispos. 14:590-600 (1986).
11. J. Craven, D. R. Hennessy, and C. Friis. Does the rate of fat deposition influence the pharmacokinetic disposition of subcutaneously administered moxidectin and ivermectin in pigs? J. Vet. Pharmacol. Ther. 25:351-357 (2002).
12. M. F. Bassissi, A. Lespine, and M. Alvinerie. Enhancement of oral moxidectin bioavailability in rabbits by lipid co-administration. Parasitol. Res. 94:188-192 (2004).
13. M. Alvinerie, J. F. Sutra, I. Cabezas, L. Rubilar, and R. Perez. Enhanced plasma availability of moxidectin in fasted horses. J. Equine Vet. Sci. 20:575-578 (2000).
14. A. Lespine, J. F. Sutra, J. Dupuy, M. Alvinerie, and G. Aumont. The influence of parasitism on the pharmacokinetics of moxidectin in lambs. Parasitol. Res. 93:121-126 (2004).
15. K. M. Wasan. Modifications in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drugs. J. Pharmacol. Toxicol. Methods 36:1-11 (1996).
16. M. Lemaire and J. P. Tillement. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J. Pharm. Pharmacol. 34:715-718 (1982).
17. A. J. Humberstone, A. F. Cowman, J. Horton, and W. N. Charman. Effect of altered serum lipid concentrations on the IC50 of halofantrine against Plasmodium falciparum. J. Pharm. Sci. 87:256-258 (1998)
18. A. J. Humberstone, C. J. Porter, G. A. Edwards, and W. N. Charman. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J. Pharm. Sci. 87:936-942 (1998).
19. K. M. Wasan, A. L. Kennedy, S. M. Cassidy, M. Ramaswamy, L. Holtorf, J. W. Chou, and P. H. Pritchard. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob. Agents Chemother. 42:3146-3152 (1998).
20. A. H. Terpstra, C. J. Woodward, and F. J. Sanchez-Muniz. Improved techniques for the separation of serum lipoproteins by density gradient ultracentrifugation: visualization by prestaining and rapid separation of serum lipoproteins from small volumes of serum. Anal. Biochem. 111:149-157 (1981).
21. C. C. Allain, L. S. Poon, C. S. Chan, W. Richmond, and P. C. Fu. Enzymatic determination of total serum cholesterol. Clin. Chem. 20:470-475 (1974).
22. M. Alvinerie, J. F. Sutra, M. Badri, and P. Galtier. Determination of moxidectin in plasma by high-performance liquid chromatography with automated solid-phase extraction and fluorescence detection. J. Chromatogr. B Biomed. Appl. 674:119-124 (1995).
23. A. Lespine, G. Chanoit, A. Bousquet-Melou, E. Lallemand, F. M. Bassissi, M. Alvinerie, and P. L. Toutain. Contribution of lymphatic transport to the systemic exposure of orally administered moxidectin in conscious lymph duct-cannulated dogs. Eur. J. Pharm. Sci. 27:37-43 (2006).
24. K. Yamaoka, Y. Tanigawara, T. Nakagawa, and T. Uno. A pharmacokinetic analysis program (Multi) for microcomputer. J. Pharmacobio-dyn. 4:879-885 (1981).
25. K. Yamaoka, T. Nakagawa, and T. Uno. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175 (1978).
26. K. M. Wasan, P. H. Pritchard, M. Ramaswamy, W. Wong, E. M. Donnachie, and L. J. Brunner. Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine. Pharm. Res. 14:1613-1620 (1997).
27. Y. C. Ha and P. J. Barter. Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp. Biochem. Physiol., B 71:265-269 (1982).
28. F. Norido, A. Zatta, C. Fiorito, M. Prosdocimi, and G. Weber. Hematologic and biochemical profiles of selectively bred WHHL rabbits. Lab. Anim. Sci. 43:319-323 (1993).
29. N. M. O'Meara, R. A. Devery, D. Owens, P. B. Collins, A. H. Johnson, and G. H. Tomkin. Serum lipoproteins and cholesterol metabolism in two hypercholesterolaemic rabbit models. Diabetologia 34:139-143 (1991).
30. K. M. Wasan, M. Ramaswamy, M. P. McIntosh, C. J. Porter, and W. N. Charman. Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: in vitro studies in normolipidemic and dyslipidemic human plasmas. J. Pharm. Sci. 88:185-190 (1999).
31. K. M. Wasan, M. Ramaswamy, W. Wong, and P. H. Pritchard. Lipid transfer protein I facilitated transfer of cyclosporine from low- to high-density lipoproteins is only partially dependent on its cholesteryl ester transfer activity. J. Pharmacol. Exp. Ther. 284:599-605 (1998).
32. R. McPherson, C. J. Mann, A. R. Tall, M. Hogue, L. Martin, R. W. Milne, and Y. L. Marcel. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler. Thromb. 11:797-804 (1991).
33. M. J. Chapman. Animal lipoproteins: chemistry, structure, and comparative aspects. J. Lipid Res. 21:789-853 (1980).
34. B. L. Kasiske, W. M. Awni, K. L. Heim-Duthoy, M. Rose, V. K. Rao, P. Bloom, A. Ney, J. Andrisevic, M. Odland, and R. C. Andersen. Alterations in cyclosporine pharmacokinetics after renal transplantation are linked to rapid increases in hematocrit, lipoproteins, and serum protein. Transplant. Proc. 20:485-486 (1988).
35. S. Rodl, G. Fuchs, G. Khoshsorur, F. Iberer, and K. H. Tscheliessnigg. Lipoprotein-induced modulation of cyclosporine-A-mediated immunosuppression. Eur. J. Clin. Investig. 20:248-252 (1990).
36. W. F. Hieb and M. Rothstein. Sterol requirement for reproduction of a free-living nematode. Science 160:778-780 (1968).
37. T. V. Kurzchalia and S. Ward. Why do worms need cholesterol? Nat. Cell Biol. 5:684-688 (2003).
38. V. Matyash, C. Geier, A. Henske, S. Mukherjee, D. Hirsh, C. Thiele, B. Grant, F. R. Maxfield, and T. V. Kurzchalia. Distribution and transport of cholesterol in Caenorhabditis elegans. Mol. Biol. Cell 12:1725-1736 (2001).
39. I. Jeusette, M. Grauwels, C. Cuvelier, C. Tonglet, L. Istasse, and M. Diez. Hypercholesterolaemia in a family of rough collie dogs. J. Small Anim. Pract. 45:319-324 (2004).
40. I. C. Jeusette, E. T. Lhoest, L. P. Istasse, and M. O. Diez. Influence of obesity on plasma lipid and lipoprotein concentrations in dogs. Am. J. Vet. Res. 66:81-86 (2005).